Literature DB >> 11547834

Tibolone exerts its protective effect on trabecular bone loss through the estrogen receptor.

A G Ederveen1, H J Kloosterboer.   

Abstract

Tibolone (Org OD14) has estrogenic, progestogenic, and/or androgenic activity depending on the tissue. In postmenopausal women, tibolone prevents bone loss without stimulating the endometrium. Tibolone is effective in preventing trabecular bone loss from the peripheral and axial skeleton of young and old ovariectomized (OVX) rats by reducing bone turnover, that is, bone resorption, like estrogens. We evaluated the contribution of the various hormonal activities to tibolone's bone-conserving effect. Three-month-old OVX rats received tibolone (125 microg/rat or 500 microg/rat, twice daily), alone or combined with an antiestrogen, antiandrogen, or antiprogestogen, and the effects on trabecular bone mass and bone turnover were evaluated. Sham-operated and control OVX groups were treated with vehicle. The remaining OVX groups received oral doses of tibolone twice daily, alone or with twice daily (a) antiestrogen ICI 164.384, (b) antiandrogen flutamide, or (c) antiprogestogen Org 31710. For comparison, the effects of 17beta-estradiol and testosterone were examined also. After 4 weeks, trabecular bone mineral density (BMD) in the distal femur, plasma osteocalcin, and urinary deoxypyridinoline/creatinine ratio (Dpyr/Cr) were measured. Tibolone or 17beta-estradiol significantly blocked ovariectomy-induced loss of trabecular BMD and inhibited bone resorption and bone turnover as judged by reduced Dpyr/Cr ratio and osteocalcin, respectively. These effects of both compounds were counteracted by the antiestrogen. This suggests a major involvement of the estrogen receptor in the action of tibolone on bone metabolism. However, the antiandrogen and the antiprogestogen did not counteract the effects of tibolone, excluding a major role of the androgenic and progestogenic activities of tibolone in its action against trabecular bone loss. The results indicate that tibolone acts on bone almost entirely through activation of the estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11547834     DOI: 10.1359/jbmr.2001.16.9.1651

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  4 in total

1.  Effect of prolonged use of high dose of tibolone on the vagina of ovariectomized rats.

Authors:  Helene Nara Henriques; Ana Carolina Bergmann de Carvalho; Porphirio José Soares Filho; José Augusto Soares Pantaleão; Maria Angélica Guzmán-Silva
Journal:  Int J Exp Pathol       Date:  2011-04-26       Impact factor: 1.925

2.  Consensus statement on the use of HRT in postmenopausal women in the management of osteoporosis by SIE, SIOMMMS and SIGO.

Authors:  L Vignozzi; N Malavolta; P Villa; G Mangili; S Migliaccio; S Lello
Journal:  J Endocrinol Invest       Date:  2018-11-19       Impact factor: 4.256

3.  The effects of tibolone in older postmenopausal women.

Authors:  Steven R Cummings; Bruce Ettinger; Pierre D Delmas; Peter Kenemans; Victoria Stathopoulos; Pierre Verweij; Mirjam Mol-Arts; Lenus Kloosterboer; Lori Mosca; Claus Christiansen; John Bilezikian; Eduardo Mario Kerzberg; Susan Johnson; Jose Zanchetta; Diederich E Grobbee; Wilfried Seifert; Richard Eastell
Journal:  N Engl J Med       Date:  2008-08-14       Impact factor: 91.245

4.  Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.

Authors:  P D Delmas; S R Davis; J Hensen; S Adami; S van Os; E A Nijland
Journal:  Osteoporos Int       Date:  2008-02-07       Impact factor: 4.507

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.